Enveric has many novel molecules with unique receptor binding profiles and pharmacokinetic properties available for out-licensing as potential drug candidates.

To the prospective partner, the molecules represent an opportunity for pipeline development and access to novel, protected compounds in a highly competitive and significant medical market.

For Enveric, the out-licensing made possible by the Psybrary™ Portfolios represents an opportunity to diversify risk while capitalizing on and retaining potential milestone payments and royalty revenue across multiple drug candidates and markets.